These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10761165)

  • 21. Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet.
    Abbas R; Palumbo D; Walters F; Belden H; Berry SA
    Clin Ther; 2016 May; 38(5):1151-7. PubMed ID: 27021606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylphenidate bioavailability from two extended-release formulations.
    González MA; Pentikis HS; Anderl N; Benedict MF; DeCory HH; Dirksen SJ; Hatch SJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):175-84. PubMed ID: 11996212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
    Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
    Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
    Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
    Weisler RH; Stark JG; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential.
    Spencer TJ; Biederman J; Martin JM; Moorehead TM; Mirto T; Clarke A; Batchelder H; Faraone SV
    Postgrad Med; 2012 Jan; 124(1):166-73. PubMed ID: 22314126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
    McBurnett K; Starr HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog.
    Giorgi M; Prise U; Soldani G; Neri D; Lavy E
    Vet Res Commun; 2010 Jun; 34 Suppl 1():S73-7. PubMed ID: 20454855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylphenidate (OROS formulation).
    Keating GM; McClellan K; Jarvis B
    CNS Drugs; 2001; 15(6):495-500; discussion 501-3. PubMed ID: 11524026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults.
    Katzman MA; Mattingly G; Klassen LJ; Cataldo MJ; Donnelly GAE
    J Clin Psychopharmacol; 2020; 40(6):579-587. PubMed ID: 33009228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users.
    Bjarnadottir GD; Johannsson M; Magnusson A; Rafnar BO; Sigurdsson E; Steingrimsson S; Asgrimsson V; Snorradottir I; Bragadottir H; Haraldsson HM
    Drug Alcohol Depend; 2017 Sep; 178():165-169. PubMed ID: 28651152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.